Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.

The oral delivery of drugs with poor aqueous solubility is challenging and often results in poor bioavailability. Various nanoformulation platforms have demonstrated improved oral bioavailability of a range of drugs for different indications. The focus of this review is to provide an overview of the application of nanomedicine to oral antiretroviral therapy and outline how the current short-falls of this life-long therapy may be resolved using nanotechnology. As well as highlighting the rationale for a nanomedicine-based approach, the review focuses on the various strategies used to enhance oral bioavailability and describes the mechanisms of particle absorption across the GI tract. The recent advances in the development of long-acting formulations for both HIV treatment and pre-exposure prophylaxis are also discussed.

[1]  D. Tomalia Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .

[2]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[3]  Omid C. Farokhzad,et al.  Polymeric nanoparticle technologies for oral drug delivery. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Yves-Jacques Schneider,et al.  An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  D. Friend,et al.  Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. , 2013, Antiviral research.

[6]  Tom O. McDonald,et al.  Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents , 2014 .

[7]  T. Chun,et al.  Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir , 2014, Proceedings of the National Academy of Sciences.

[8]  Nutan,et al.  Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS , 2013, HIV/AIDS.

[9]  C. Destache,et al.  Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. , 2013, AIDS research and human retroviruses.

[10]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[11]  Yuanjie Liu,et al.  Dual-functionalized PAMAM dendrimers with improved P-glycoprotein inhibition and tight junction modulating effect. , 2013, Biomacromolecules.

[12]  Nicholas A Peppas,et al.  Therapeutic applications of hydrogels in oral drug delivery , 2014, Expert opinion on drug delivery.

[13]  Jinming Gao,et al.  Nanonization strategies for poorly water-soluble drugs. , 2011, Drug discovery today.

[14]  Kinam Park,et al.  Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. , 2013, International journal of pharmaceutics.

[15]  J. Lovrić,et al.  Nanotherapeutics in the EU: an overview on current state and future directions , 2014, International journal of nanomedicine.

[16]  Laura M Ensign,et al.  Nanoparticle-based drug delivery to the vagina: a review. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Sung-Joo Hwang,et al.  A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[18]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[19]  J. Iqbal,et al.  Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Patrick Augustijns,et al.  Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.

[21]  David R. Holtgrave Causes of the decline in AIDS deaths, United States, 1995–2002: prevention, treatment or both? , 2005, International journal of STD & AIDS.

[22]  Frederic Lagarce,et al.  Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. , 2010, Nanomedicine.

[23]  S. Khoo,et al.  Intracellular pharmacokinetics of antiretroviral agents. , 2004, Journal of HIV therapy.

[24]  A. Lázníčková,et al.  Dendrimers: Analytical characterization and applications. , 2009, Bioorganic chemistry.

[25]  S. Garg,et al.  Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. , 2010, Advanced drug delivery reviews.

[26]  H. Ghandehari,et al.  Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. , 2012, Advanced drug delivery reviews.

[27]  David J Brayden,et al.  Expression of specific markers and particle transport in a new human intestinal M-cell model. , 2000, Biochemical and biophysical research communications.

[28]  H. Mahajan,et al.  Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting , 2014, Drug delivery.

[29]  Jennifer P. Freeling,et al.  Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. , 2014, Journal of pharmaceutical sciences.

[30]  Lin Zhang,et al.  Nanocarriers for oral drug delivery , 2013, Journal of drug targeting.

[31]  Heike Bunjes,et al.  Lipid nanoparticles for the delivery of poorly water‐soluble drugs , 2010, The Journal of pharmacy and pharmacology.

[32]  S. Lucangioli,et al.  Novel nelfinavir mesylate loaded d-α-tocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: In vitro characterization and in vivo evaluation. , 2014, Colloids and surfaces. B, Biointerfaces.

[33]  Gwo-Yu Chuang,et al.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.

[34]  H. Gendelman,et al.  Comparative manufacture and cell-based delivery of antiretroviral nanoformulations , 2011, International journal of nanomedicine.

[35]  Gordon L. Amidon,et al.  Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs , 2009, The AAPS Journal.

[36]  P. Desai,et al.  Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. , 2012, Drug discovery today. Technologies.

[37]  P. Sinko,et al.  Oral absorption of the HIV protease inhibitors: a current update. , 1999, Advanced drug delivery reviews.

[38]  Amit Jain,et al.  Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. , 2013, Nanomedicine.

[39]  Amit Jain,et al.  Nanotechnology: A magic bullet for HIV AIDS treatment , 2015, Artificial cells, nanomedicine, and biotechnology.

[40]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[41]  Lee M. Tatham,et al.  Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium† †Electronic supplementary information (ESI) available: Materials, full experimental details and characterisation. See DOI: 10.1039/c4sc02889a Click here for additional data file. , 2014, Chemical science.

[42]  D. Ho,et al.  Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus , 2014, Science.

[43]  D. Chiappetta,et al.  Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. , 2011, Biomaterials.

[44]  C. Destache,et al.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. , 2013, Biomaterials.

[45]  H. Sharma,et al.  Conference scene: Nanoneuroprotection and nanoneurotoxicity: recent progress and future perspectives. , 2010, Nanomedicine.

[46]  D. Chiappetta,et al.  Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. , 2010, Nanomedicine.

[47]  V. Préat,et al.  Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. , 2014, International journal of pharmaceutics.

[48]  M Laird Forrest,et al.  Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. , 2011, Advanced drug delivery reviews.

[49]  Bing Xu,et al.  Self‐Delivery Multifunctional Anti‐HIV Hydrogels for Sustained Release , 2013, Advanced healthcare materials.

[50]  Yves-Jacques Schneider,et al.  Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[51]  A. Carcaboso,et al.  Nanomedicines in the future of pediatric therapy. , 2014, Advanced drug delivery reviews.

[52]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[53]  E. Dolgin Long-acting HIV drugs advanced to overcome adherence challenge , 2014, Nature Medicine.

[54]  M. Chikindas,et al.  Polyethylene Glycol-Based Hydrogels for Controlled Release of the Antimicrobial Subtilosin for Prophylaxis of Bacterial Vaginosis , 2014, Antimicrobial Agents and Chemotherapy.

[55]  Steve Rannard,et al.  Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems , 2012 .

[56]  R. Gurny,et al.  Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilicity. , 2010, International journal of pharmaceutics.

[57]  M. Bäckström,et al.  Composition and functional role of the mucus layers in the intestine , 2011, Cellular and Molecular Life Sciences.

[58]  P. Swaan,et al.  Potential Oral Delivery of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) using Poly(amidoamine) Dendrimers , 2008, Pharmaceutical Research.

[59]  H. Gendelman,et al.  Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[60]  L. Rohan,et al.  Progress in antiretroviral drug delivery using nanotechnology , 2010, International journal of nanomedicine.

[61]  H. Gendelman,et al.  Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[62]  P. Ortega,et al.  Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[63]  Omid C Farokhzad,et al.  Insight into nanoparticle cellular uptake and intracellular targeting. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Dong Wang,et al.  Formation and enhanced biocidal activity of water-dispersable organic nanoparticles. , 2008, Nature nanotechnology.

[65]  A. Concheiro,et al.  N-alkylation of poloxamines modulates micellar assembly and encapsulation and release of the antiretroviral efavirenz. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[66]  J. Meza,et al.  Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. , 2013, Nanomedicine.

[67]  J. Gao,et al.  Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). , 2007, Journal of pharmaceutical sciences.

[68]  S. Moghimi,et al.  Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. , 2012, Maturitas.

[69]  X. Langlois,et al.  Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[70]  P. Gorry,et al.  Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. , 2011, Antiviral research.

[71]  V. Bhardwaj,et al.  Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[72]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[73]  H. Gendelman,et al.  Macrophage endocytic trafficking of antiretroviral nanoparticles. , 2011, Nanomedicine.

[74]  I. Zuhorn,et al.  Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.

[75]  M. Schoenfisch,et al.  Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. , 2007, Biomacromolecules.

[76]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[77]  A. Hubbard,et al.  Transcytosis: crossing cellular barriers. , 2003, Physiological reviews.

[78]  D. Mcclements Nanoemulsion-based oral delivery systems for lipophilic bioactive components: nutraceuticals and pharmaceuticals. , 2013, Therapeutic delivery.

[79]  Jia-You Fang,et al.  Nanostructured lipid carriers (NLCs) for drug delivery and targeting. , 2012, Recent patents on nanotechnology.

[80]  C. Giaquinto,et al.  Current and Future Antiretroviral Treatment Options in Paediatric HIV Infection , 2008, Clinical drug investigation.

[81]  Michael J Akers,et al.  Excipient-drug interactions in parenteral formulations. , 2002, Journal of pharmaceutical sciences.

[82]  N. K. Jain,et al.  Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[83]  Sanyog Jain,et al.  Solid lipid nanoparticles: an oral bioavailability enhancer vehicle , 2011, Expert opinion on drug delivery.

[84]  Qiang Zhang,et al.  The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. , 2013, Biomaterials.

[85]  M. Loza,et al.  Inhibition of P-glycoprotein pumps by PEO-PPO amphiphiles: branched versus linear derivatives. , 2010, Nanomedicine.

[86]  P. Chattopadhyay,et al.  Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[87]  Rolf Kaiser,et al.  HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice , 2013, Proceedings of the National Academy of Sciences.

[88]  E. Merisko-Liversidge,et al.  Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds , 2008, Toxicologic pathology.

[89]  Christopher J H Porter,et al.  Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update☆ , 2007, Advanced Drug Delivery Reviews.

[90]  S. Benita,et al.  Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[91]  T. Chun,et al.  Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses , 2008, Mucosal Immunology.

[92]  M. R. Kumar,et al.  PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. , 2008, Journal of pharmaceutical sciences.

[93]  E. Garvey,et al.  Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection , 2014, Antimicrobial Agents and Chemotherapy.

[94]  Lieven Baert,et al.  Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[95]  Marina A Dobrovolskaia,et al.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[96]  A. Schätzlein,et al.  Dendrimers in gene delivery. , 2005, Advanced drug delivery reviews.

[97]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[98]  F. Veiga,et al.  Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[99]  A. Ivanov,et al.  Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? , 2008, Methods in molecular biology.

[100]  Rongqin Huang,et al.  Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. , 2008, Journal of pharmaceutical sciences.

[101]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[102]  Tom O. McDonald,et al.  Nanomedicines for HIV therapy. , 2013, Therapeutic delivery.

[103]  Alexander V Kabanov,et al.  Pluronic block copolymers for overcoming drug resistance in cancer. , 2002, Advanced drug delivery reviews.

[104]  E. R. de Celis,et al.  Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[105]  Shufeng Zhou,et al.  Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. , 2004, Current drug metabolism.

[106]  Patrice D Cani,et al.  Targeted nanoparticles with novel non-peptidic ligands for oral delivery. , 2013, Advanced drug delivery reviews.

[107]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[108]  H. Gendelman,et al.  Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[109]  D. Chiappetta,et al.  Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. , 2013, Nanomedicine.

[110]  E. Souto,et al.  Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[111]  H. Gendelman,et al.  Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy , 2013, Antimicrobial Agents and Chemotherapy.

[112]  Tushar K. Vyas,et al.  Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. , 2008, International journal of pharmaceutics.

[113]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[114]  Glenn E. M. Maguire,et al.  Nanotechnology and the Treatment of HIV Infection , 2012, Viruses.

[115]  Y. Barenholz,et al.  Annals of the New York Academy of Sciences Nanomedicines: Addressing the Scientific and Regulatory Gap , 2022 .

[116]  Darren L. Smith,et al.  Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation , 2014, Advanced healthcare materials.

[117]  S. Piscitelli,et al.  GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects , 2014, Journal of acquired immune deficiency syndromes.

[118]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[119]  R. Müller,et al.  Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery , 2008, Drug development and industrial pharmacy.

[120]  Sonke Svenson,et al.  Dendrimers as versatile platform in drug delivery applications. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[121]  D. Mcclements,et al.  Delivery of lipophilic bioactives: assembly, disassembly, and reassembly of lipid nanoparticles. , 2014, Annual review of food science and technology.

[122]  M. R. Kumar,et al.  Oral Nanoparticulate Atorvastatin Calcium is More Efficient and Safe in Comparison to Lipicure® in Treating Hyperlipidemia , 2008, Lipids.

[123]  B. Aungst,et al.  P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. , 1999, Advanced drug delivery reviews.

[124]  P. Sinko,et al.  Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. , 2010, Advanced drug delivery reviews.

[125]  J. Shuter,et al.  Lopinavir/ritonavir in the treatment of HIV-1 infection: a review , 2008, Therapeutics and clinical risk management.

[126]  R. Langer,et al.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. , 2010, Nanomedicine.

[127]  S. Piscitelli,et al.  Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor , 2013, HIV clinical trials.

[128]  Rakesh K. Sharma,et al.  Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation. , 2014, International journal of pharmaceutics.

[129]  P. Ravi,et al.  Design, optimization and evaluation of poly-ɛ-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir , 2015, Drug development and industrial pharmacy.

[130]  M. Varma,et al.  Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[131]  Nazila Salamat-Miller,et al.  Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. , 2005, International journal of pharmaceutics.

[132]  Abu T M Serajuddin,et al.  Salt formation to improve drug solubility. , 2007, Advanced drug delivery reviews.

[133]  P. Sylvester,et al.  Enhancement of Intestinal Permeability Utilizing Solid Lipid Nanoparticles Increases γ-Tocotrienol Oral Bioavailability , 2012, Lipids.

[134]  V. Préat,et al.  Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[135]  L. Stanberry,et al.  VivaGel™ (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection , 2007, International journal of nanomedicine.

[136]  J. Irache,et al.  Nanomedicine: novel approaches in human and veterinary therapeutics. , 2011, Veterinary parasitology.

[137]  H. Santos,et al.  Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. , 2012, Current drug metabolism.

[138]  B. Sarmento,et al.  Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. , 2010, Advanced drug delivery reviews.

[139]  Hamidreza Ghandehari,et al.  Endocytosis and Interaction of Poly (Amidoamine) Dendrimers with Caco-2 Cells , 2007, Pharmaceutical Research.

[140]  Michael Riediker,et al.  Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.

[141]  Jennifer P. Freeling,et al.  Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence , 2014, Proceedings of the National Academy of Sciences.

[142]  Lieven Baert,et al.  Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation , 2010, Antimicrobial Agents and Chemotherapy.